Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH.

Trends Immunol. 2019 Jun;40(6):511-523. doi: 10.1016/j.it.2019.04.002. Epub 2019 Apr 30. Review.

PMID:
31053497
2.

Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes.

Osum KC, Burrack AL, Martinov T, Sahli NL, Mitchell JS, Tucker CG, Pauken KE, Papas K, Appakalai B, Spanier JA, Fife BT.

Sci Rep. 2018 May 29;8(1):8295. doi: 10.1038/s41598-018-26471-9.

3.

The diverse functions of the PD1 inhibitory pathway.

Sharpe AH, Pauken KE.

Nat Rev Immunol. 2018 Mar;18(3):153-167. doi: 10.1038/nri.2017.108. Epub 2017 Nov 13. Review.

PMID:
28990585
4.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

5.

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ.

Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.

6.

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, Wherry EJ.

Science. 2016 Dec 2;354(6316):1160-1165. Epub 2016 Oct 27.

7.

PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes.

Martinov T, Spanier JA, Pauken KE, Fife BT.

Immunoendocrinology (Houst). 2016;3. pii: e1164.

8.

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, Wherry EJ.

Immunity. 2016 Aug 16;45(2):358-73. doi: 10.1016/j.immuni.2016.07.008. Epub 2016 Aug 2.

9.

Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity.

Manlove LS, Schenkel JM, Manlove KR, Pauken KE, Williams RT, Vezys V, Farrar MA.

J Immunol. 2016 Jun 1;196(11):4793-804. doi: 10.4049/jimmunol.1600130. Epub 2016 Apr 25.

10.

IL-15-Independent Maintenance of Tissue-Resident and Boosted Effector Memory CD8 T Cells.

Schenkel JM, Fraser KA, Casey KA, Beura LK, Pauken KE, Vezys V, Masopust D.

J Immunol. 2016 May 1;196(9):3920-6. doi: 10.4049/jimmunol.1502337. Epub 2016 Mar 21.

11.

CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors.

Kalekar LA, Schmiel SE, Nandiwada SL, Lam WY, Barsness LO, Zhang N, Stritesky GL, Malhotra D, Pauken KE, Linehan JL, O'Sullivan MG, Fife BT, Hogquist KA, Jenkins MK, Mueller DL.

Nat Immunol. 2016 Mar;17(3):304-14. doi: 10.1038/ni.3331. Epub 2016 Feb 1.

12.

SnapShot: T Cell Exhaustion.

Pauken KE, Wherry EJ.

Cell. 2015 Nov 5;163(4):1038-1038.e1. doi: 10.1016/j.cell.2015.10.054. No abstract available.

13.

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, Wherry EJ, Alter G, Goulder PJ, Klenerman P, Sharpe AH, Lauer GM, Haining WN.

PLoS Pathog. 2015 Oct 20;11(10):e1005177. doi: 10.1371/journal.ppat.1005177. eCollection 2015 Oct.

14.

Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.

Manlove LS, Berquam-Vrieze KE, Pauken KE, Williams RT, Jenkins MK, Farrar MA.

J Immunol. 2015 Oct 15;195(8):4028-37. doi: 10.4049/jimmunol.1501291. Epub 2015 Sep 16.

15.

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.

Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ.

J Exp Med. 2015 Jun 29;212(7):1125-37. doi: 10.1084/jem.20142237. Epub 2015 Jun 1.

16.

Overcoming T cell exhaustion in infection and cancer.

Pauken KE, Wherry EJ.

Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18. Review.

17.

Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.

Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, Quarnstrom CF, Osum KC, Schenkel JM, Jenkins MK, Blazar BR, Vezys V, Fife BT.

J Immunol. 2015 Apr 15;194(8):3551-3555. doi: 10.4049/jimmunol.1402262. Epub 2015 Mar 13.

18.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

19.

TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.

Pauken KE, Wherry EJ.

Cancer Cell. 2014 Dec 8;26(6):785-787. doi: 10.1016/j.ccell.2014.11.016.

20.

T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses.

Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D.

Science. 2014 Oct 3;346(6205):98-101. doi: 10.1126/science.1254536. Epub 2014 Aug 28.

21.

Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice.

Pauken KE, Linehan JL, Spanier JA, Sahli NL, Kalekar LA, Binstadt BA, Moon JJ, Mueller DL, Jenkins MK, Fife BT.

J Immunol. 2013 Nov 15;191(10):4913-7. doi: 10.4049/jimmunol.1301927. Epub 2013 Oct 11.

22.

PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.

Pauken KE, Jenkins MK, Azuma M, Fife BT.

Diabetes. 2013 Aug;62(8):2859-69. doi: 10.2337/db12-1475. Epub 2013 Apr 4.

23.

The role of the PD-1 pathway in autoimmunity and peripheral tolerance.

Fife BT, Pauken KE.

Ann N Y Acad Sci. 2011 Jan;1217:45-59. doi: 10.1111/j.1749-6632.2010.05919.x. Review.

PMID:
21276005
24.

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA.

Nat Immunol. 2009 Nov;10(11):1185-92. doi: 10.1038/ni.1790. Epub 2009 Sep 27.

Supplemental Content

Loading ...
Support Center